The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
Open accessAbstract
Paclitaxel (PTX) is one of the most effective anticancer agents. In clinical practice, however, high incidences of adverse reactions of the drug, for example, neurotoxicity, myelosuppression, and allergic reactions, have been reported. NK105, a micellar nanoparticle formulation, was developed to overcome these problems and to enhance the antitumour activity of PTX. Via the self-association process, PTX was incorporated into the inner core of the micelle system by physical entrapment through hydrophobic interactions between the drug and the well-designed block copolymers for PTX. NK105 was compared with free PTX with respect to their in vitro cytotoxicity, in vivo antitumour activity, pharmacokinetics, pharmacodynamics, and neurotoxicity. Consequently, the plasma area under the curve (AUC) values were approximately 90-fold higher for NK105 than for free PTX because the leakage of PTX from normal blood vessels was minimal and its capture by the reticuloendothelial system minimised. Thus, the tumour AUC value was 25-fold higher for NK105 than for free PTX. NK105 showed significantly potent antitumour activity on a human colorectal cancer cell line HT-29 xenograft as compared with PTX (P<0.001) because the enhanced accumulation of the drug in the tumour has occurred, probably followed by its effective and sustained release from micellar nanoparticles. Neurotoxicity was significantly weaker with NK105 than with free PTX. The neurotoxicity of PTX was attenuated by NK105, which was demonstrated by both histopathological (P<0.001) and physiological (P<0.05) methods for the first time. The present study suggests that NK105 warrants a clinical trial for patients with metastatic solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The size of polymeric micelles currently in clinical trials are less than 100 nm [6, 7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NK105 exhibited 23% of drug loading with a hydrodynamic size of approx. 90 nm [7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“NK105 is composed of paclitaxel and modified mPEG-b-P(Asp) block copolymer (mPEG = 12,000 g/mol and P(Asp) = 8,000 g/mol) where half of the carboxylic groups P(Asp) block is modified with hydrophobic 4-phenyl-1-butanol to increase its hydrophobicity and improve drug incorporation [7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Self-citationRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles
Savić, R., Luo, L., Eisenberg, A., & Maysinger, D. (2003) · Science · doi:10.1126/science.1078192 · Cited by 1,113
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Block copolymer micelles as vehicles for drug delivery
Kazunori, K., Glenn S., K., Masayuki, Y., Teruo, O., & Yasuhisa, S. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90172-2 · Cited by 877
Self-citationKim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Development of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570
Self-citation
Research works printed but not linked: 1
- Hamaguchi T, Matsumura Y, Shirao Y, Shimada Y, Yamada Y, Muro Y, Okusaka T, Ueno H, Ikeda M, Watanabe N (2003) Phase I study of novel drug delivery system, NK911, a polymer micelle encapsulated doxorubicin. Proc Am Soc Clin Oncol 22: 571
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Shape effects of filaments versus spherical particles in flow and drug delivery
Geng, Y., Dalhaimer, P., Cai, S., Tsai, R., Tewari, M., Minko, T., & Discher, D. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.70 · Cited by 2,565
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Metadata
- Authors
- Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T.
- Affiliations
- National Cancer Centre Japan (JP)
- Nippon Kayaku (Japan) (JP)
- NanoCarrier (Japan) (JP)
- Kanagawa Academy of Science and Technology (JP)
- The University of Tokyo (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-03-22
- Volume
- 92
- Issue
- 7
- Pages
- 1240-1246
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361981
- OpenAlex
- W2112927879
- Cited by
- 565
- References
- 23
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 18 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 29 · 2019: 21 · 2018: 27 · 2017: 36 · 2016: 41 · 2015: 50 · 2014: 40 · 2013: 29 · 2012: 33
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, micellar nanoparticles, nanoparticle drug delivery, neurotoxicity, antitumour activity, pharmacokinetics, pharmacodynamics, block copolymer micelles, colorectal cancer, HT-29 xenograft, drug leakage, sustained drug release, metastatic solid tumors
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Colonic Neoplasms, Humans, Nervous System, Transplantation, Heterologous, Paclitaxel, Area Under Curve, Nanostructures, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. https://app.cochat.ai/papers/10.1038/sj.bjc.6602479
- The paper
- Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005). NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6602479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.